Risk-Adapted Starting Age of CRC Screening Varies by Sex, Genetics
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 30, 2023 -- Risk-adapted starting ages of screening vary by sex and polygenic risk score (PRS) among individuals at average risk for colorectal cancer (CRC), according to a study published online Oct. 25 in JAMA Network Open.
Xuechen Chen, Ph.D., from the German Cancer Research Center in Heidelberg, and colleagues illustrated derivation of risk-adjusted starting ages of CRC screening based on the concept of risk advanced period (RAP) using sex and PRS. Participants were from the U.K. Biobank (aged 40 to 69 years) with no family history of CRC and no previous bowel cancer screening.
Overall, 2,714 incident CRC cases were identified during a median follow-up of 11.2 years and 758 deaths were reported during a median follow-up of 12.8 years among 242,779 participants. The researchers found that for men versus women, the hazard ratios of CRC risk were 1.57 and ranged from 0.51 to 2.29 across PRS deciles compared with the reference. For men versus women, the RAPs were 5.6 years and varied from −8.4 to 10.3 years across PRS deciles when compared with the reference deciles. For men in the highest PRS decile versus women in the lowest PRS decile, risk-adapted starting ages of screening would vary by 24 years. Regarding CRC mortality, results were similar.
"The RAP approach could be easily extended to incorporate additional risk factor information," the authors write. "Further research should assess the feasibility, acceptance, and cost-effectiveness of the use of this approach."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.